title: Implementing quality by design for biotech products: Are regulators on track?
abstract: Quality by design (QbD) is an innovative approach to drug development that has started to be implemented into the regulatory framework, but currently mainly for chemical drugs. The recent marketing authorization of the first monoclonal antibody developed using extensive QbD concepts in the European Union paves the way for future further regulatory approvals of complex products employing this cutting-edge technological concept. In this paper, we report and comment on insights and lessons learnt from the non-public discussions in the European Medicines Agency's Biologicals Working Party and Committee for Medicinal Products for Human Use on the key issues during evaluation related to the implementation of an extensive QbD approach for biotechnology-derived medicinal products. Sharing these insights could prove useful for future developments in QbD for biotech products in general and monoclonal antibodies in particular.
authors: a National Center for Immunobiologicals Control and Evaluation (CRIVIB); Istituto Superiore di Sanità ; Rome , Italy.
authors: Francesca
authors: F
authors: Luciani
authors: Sara
authors: S
authors: Galluzzo
authors: Andrea
authors: A
authors: Gaggioli
authors: Nanna Aaby
authors: NA
authors: Kruse
authors: Pascal
authors: P
authors: Venneugues
authors: Christian K
authors: CK
authors: Schneider
authors: Carlo
authors: C
authors: Pini
authors: Daniela
authors: D
authors: Melchiorri
mesh_terms: D000911:Antibodies, Monoclonal; D001709:Biotechnology / Q000379:methods / Q000592:standards*; D005062:European Union; D006801:Humans; D011786:Quality Control
chemical_list: D000911:Antibodies, Monoclonal
keywords: BWP, Biologics Working Party; CHMP, Committee for Medicinal Products for Human Use; CPPs, critical process parameters; CQAs, critical quality attributes; EMA, European Medicines Agency; QTPP, Quality Target Product Profile; QbD, quality by design; quality by design, biotech product